Darwin Global Management »

Cytokinetics shares owned by Darwin Global Management

Quarter-by-quarter ownership of Cytokinetics (CYTK) shares owned by Darwin Global Management from 13F filings

Historical chart of Darwin Global Management investment in Cytokinetics

Tip: Access up to 7 years of quarterly data

All positions including Cytokinetics held by Darwin Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cytokinetics by Darwin Global Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $50M 600k 83.49

More positions owned by Darwin Global Management

Ambrx Biopharma
Tg Therapeutics (TGTX)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Vaxcyte (PCVX)
Springworks Therapeutics (SWTX)
Nuvalent Inc-a (NUVL)

View all positions for Darwin Global Management

Top funds holding Cytokinetics

Vanguard Group
Wellington Management Company
Caption Management
T. Rowe Price Associates
Henderson Group
Boxer Capital
Citadel Advisors
Partner Fund Management
Logos Global Management
Lord, Abbett & Co
Millennium Management
Artal Group
Barclays
Gts Securities
Goldman Sachs Group

View all funds holding Cytokinetics